Back to Journals » OncoTargets and Therapy » Volume 16

miR-139-5p Regulates Proliferation, Apoptosis, and Cell Cycle of Uterine Leiomyoma Cells by Targeting TPD52 [Retraction]

Authors Chen H, Xu H, Meng YG, Zhang Y, Chen JY, Wei XN

Received 26 June 2023

Accepted for publication 26 June 2023

Published 27 June 2023 Volume 2023:16 Pages 475—476

DOI https://doi.org/10.2147/OTT.S427667



Chen H, Xu H, Meng YG, Zhang Y, Chen JY, Wei XN. Onco Targets Ther. 2016;9:6151–6160.

We, the Editor and Publisher of OncoTargets and Therapy are retracting the published article. Since publication, concerns have been raised about the integrity of the data in the article. In addition, images from Figure S1 were found to have been duplicated. Specifically,

  • The image for Figure S1, Culture A, α-actin, has been duplicated with the image for Figure S1, Culture B, α-actin.
  • The image for Figure S1, Culture A, Merge, has been duplicated with the image for Figure S1, Culture B, Merge.

When approached for an explanation, the authors have been unable to address the concerns raised and have not been able to provide sufficient supporting information. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The authors listed in this publication have been informed.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper


Creative Commons License © 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.